Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly EBITDA Margin of 1220.09% in Q1 2026, up 38.96% quarter-over-quarter from 1998.77% in Q4 2025, and up 2529930.0% on a YoY basis from N/an in Q1 2025.
Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 1220.09% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 2529930.0% year-over-year to 1220.09%; the TTM figure through Mar 2026 stood at 2765.2% (up 4018217.0% YoY), while the FY2025 annual figure was 6034.5%, up 2268754.0% from the prior year.
- EBITDA Margin was 1220.09% for Q1 2026 at Crinetics Pharmaceuticals, up from 1998.77% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1163.75% in Q1 2022 to a low of 90572.03% in Q3 2025.
- Historically, EBITDA Margin has averaged 15049.55% across 5 years, with a median of 9717.66% in 2022.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin plunged 1593236 bps in 2025, then jumped 2529930 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 6193.51% in 2022, then slumped by 164 bps to 16363.58% in 2023, then retreated by 14 bps to 18645.36% in 2024, then surged by 89 bps to 1998.77% in 2025, then soared by 39 bps to 1220.09% in 2026.
- The last three EBITDA Margin figures came in at 1220.09% (Q1 2026), 1998.77% (Q4 2025), and 90572.03% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | -1,220.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,220.09% |
| Dec 31, 2025 | -1,998.77% |
| Sep 30, 2025 | -90,572.03% |
| Jun 30, 2025 | -11,252.96% |
| Mar 31, 2025 | -26,519.39% |
| Jun 30, 2024 | -18,645.36% |
| Mar 31, 2024 | -10,587.03% |
| Sep 30, 2023 | -16,363.58% |
| Jun 30, 2023 | -5,077.94% |
| Mar 31, 2023 | -1,663.98% |
| Dec 31, 2022 | -6,193.51% |
| Sep 30, 2022 | -9,457.64% |
| Jun 30, 2022 | -9,977.68% |
| Mar 31, 2022 | -1,163.75% |
| Dec 31, 2021 | -2,890.91% |
| Dec 31, 2020 | 30,507.04% |
| Mar 31, 2020 | -24,423.94% |
| Dec 31, 2019 | -4,547.98% |
| Sep 30, 2019 | -2,864.55% |
| Mar 31, 2019 | -2,433.79% |